Anticoagulation therapy in patients with atrial fibrillation and cerebral amyloid angiopathy

1. Hijazi Z, Oldgren J, Lindbäck J et al. The novel biomarker-based abc (age, bio markers, clinical history)-bleed ing risk score for patients with atrial fibrillation: a derivation and validation study. Lancet 2016; 387(10035): 2302– 2311. doi: 10.1016/ S0140-6736(16)00741-8.

2. Charidimou A, Boulouis G, Shams S et al. Intracerebral haemorhage risk in microbleed-positive ischaemic stroke patients with atrial fibrillation: preliminary meta-analysis of cohorts and anticoagulation decision schema. J Neurol Sci 2017; 378: 102– 109. doi: 10.1016/ j.

jns.2017.04.042.

3. Kirchhof P, Benus si S, Kotecha D et al. 2016 esc guidelines for the management of atrial fibrillation developed in collaboration with eacts. Eur Heart J 2016; 37(38): 2893– 2962. doi: 10.1093/ eurheartj/ ehw210.

4. O’Don nell M, Eikelboom J, Yusuf S et al. Effect of apixaban on brain infarction and microbleeds: averroes-mri assessment study. Am Heart J 2016; 178: 145– 150. doi: 10.1016/ j.ahj.2016.03.019.

5. Reddy VY, Gibson DN, Kar S et al. Post-approval us experience with left atrial appendage closure for stroke prevention in atrial fibrillation. J Am Coll Cardiol 2017;

69(3): 253– 261. doi: 10.1016/ j.jacc.2016.10.010.

6. Holmes DR, Reddy VY, Turi ZG et al. Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation:

a randomised non-inferiority trial. Lancet 2009; 374(9689): 534– 542. doi: 10.1016/ S0140-6736(09)61343-X.

7. Korsholm K, Nielsen KM, Jensen JM et al. Transcatheter left atrial appendage occlusion in patients with atrial fibrillation and a high bleeding risk using aspirin alone

for post-implant antithrombotic therapy. EuroIntervention 2017; 12(17): 2075– 2082. doi: 10.4244/ EIJ-D-16-00726.